Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Primary Biliary Cholangitis: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
2018-003365-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in primary biliary cholangitis (PBC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in alkaline phosphatase (ALP). Started Feb 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2018-003365-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003365-34.